Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innoviva (INVA) Non-cash Items (2011 - 2025)

Innoviva posted quarterly Non-cash Items of $1.3 million for Q4 2025, down 74.64% year-on-year from $5.0 million in Q4 2024, and down 74.64% on a QoQ basis from $5.0 million in Q4 2024.

Innoviva (INVA) has 13 years of Non-cash Items data on file, last reported at $1.3 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-cash Items fell 74.64% year-over-year to $1.3 million; the trailing twelve-month figure through Dec 2025 stood at $1.3 million (down 74.64% YoY), and the FY2025 full-year result was $1.3 million, up 66.85% from the prior year.
  • Non-cash Items for Q4 2025 stood at $1.3 million, down from $5.0 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $5.0 million in Q4 2024 and bottomed at $1.3 million in Q4 2025.
  • The 4-year median for Non-cash Items is $2.4 million (2021), against an average of $2.8 million.
  • The widest annual swing landed in 2024, when Non-cash Items jumped 38.89%; it then slumped 74.64% in 2025.
  • A 4-year view of Non-cash Items shows it stood at $1.3 million in 2021, then jumped by 176.92% to $3.6 million in 2023, then soared by 38.89% to $5.0 million in 2024, then plunged by 74.64% to $1.3 million in 2025.
  • The last three Non-cash Items figures came in at $1.3 million (Q4 2025), $5.0 million (Q4 2024), and $3.6 million (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Innoviva 1.60 Bn 992.84 Mn 75.83 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 1.27 Mn
Dec 31, 2025 1.27 Mn
Dec 31, 2024 5.00 Mn
Dec 31, 2024 5.00 Mn
Dec 31, 2023 3.60 Mn
Dec 31, 2023 3.60 Mn
Dec 31, 2021 1.30 Mn
Dec 31, 2021 1.30 Mn
Dec 31, 2019 100,000.00
Dec 31, 2019 100,000.00
Dec 31, 2018 800,000.00
Dec 31, 2018 800,000.00
Dec 31, 2017 400,000.00
Dec 31, 2017 400,000.00
Dec 31, 2016 100,000.00
Dec 31, 2016 100,000.00
Dec 31, 2015 100,000.00
Dec 31, 2015 100,000.00
Dec 31, 2014 700,000.00
Dec 31, 2014 700,000.00
Dec 31, 2013 51.20 Mn
Dec 31, 2013 51.20 Mn
Dec 31, 2012 30.00 Mn
Dec 31, 2012 30.00 Mn
Dec 31, 2011 42.60 Mn
Dec 31, 2011 42.60 Mn